TET2

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

HTG Highlights the Advantages of Its Drug Discovery Engine

Retrieved on: 
Tuesday, May 16, 2023
TET2, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, HTG, University, Cancer, Gene expression, Cell, RNA, Acute myeloid leukemia, Chemistry, AML, Standard of care, School, Drug discovery, Artificial intelligence, Biology, FLT3, AI, University of California, Irvine School of Physical Sciences, Therapy, SVP, Gene, Behavior, Dean (education), Pharmaceutical industry, Pharmacy, Research

TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business.

Key Points: 
  • TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business.
  • HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design.
  • Currently, the company’s most advanced discovery programs are in oncology with an emphasis on the treatment of acute myeloid leukemia (AML).
  • “I see the data that our team has generated in these studies as a tangible demonstration of the power of the drug discovery engine we have built,” said Dr. Stephen A. Barat, SVP of Therapeutics at HTG.

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, Abstract, TET2, DNA, European Hematology Association, TI, Imetelstat, Chromosome, Infection, RNA, VAF, MDS, Corporation, ASXL1, Geron Corporation, Patient, Risk, CEST, Cytopenia, EHA, Public, RS, Transfusion-associated circulatory overload, DNA methylation, Gene, Thrombocytopenia, RNA splicing, Fatigue, Pharmaceutical industry, DNMT3A, SF3B1

The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.

Key Points: 
  • The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
  • As reported in January, 39.8% (47/118) of imetelstat-treated patients versus 15.0% (9/60) of placebo-treated patients achieved the study primary endpoint of 8-week TI (P
  • As noted in the abstract, a main therapeutic goal in lower risk MDS is to alter disease biology by eradicating malignant clones.
  • Of the 178 patients enrolled in IMerge Phase 3, 22.0% of imetelstat-treated patients and 21.7% of placebo-treated patients had baseline cytogenetic abnormalities.

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Retrieved on: 
Wednesday, January 4, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Hematology, Weakness, MF, Anemia, Food, TI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, LFT, Peripheral edema, DNMT3A, Diarrhea, NDA, ESA, Reverse transcriptase, Risk, Cytopenia, Disease, ASXL1, Patient, Imetelstat, IWG, Febrile neutropenia, Infection, Mutation, Brain Quest Grades 3 & 4, Safety, Marketing, Neutropenia, Headache, MAA, Thrombocytopenia, MDS, TET2, Fast Track, Pharmaceutical industry, EU

Imetelstat patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in RBC transfusion units compared to placebo.

Key Points: 
  • Imetelstat patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in RBC transfusion units compared to placebo.
  • “The notable results from IMerge Phase 3 underscore our belief that, with the unique mechanism of action of imetelstat as a telomerase inhibitor, the drug has the potential to become a first-in-class therapy for lower risk MDS patients.
  • “The IMerge Phase 3 efficacy results illustrate the depth, breadth and durability of transfusion independence potentially achievable with imetelstat treatment, which could be practice changing, if approved.
  • A conference call with Geron management to review the IMerge Phase 3 top-line results is scheduled at 8 a.m. Eastern Time this morning and may be accessed on Geron’s website.

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Retrieved on: 
Monday, October 3, 2022
Chronic myelomonocytic leukemia, Association, Translational research, CLL, Lymphoma, TET2, RHOA, JCA, Research, Myelodysplastic syndrome, Disease, Lymphatic system, SF, AML, Infection, Chronic lymphocytic leukemia, Japanese Cancer Association, CHF, Acute myeloid leukemia, Medicine, Oncogene, Dasatinib, Safety, RNA, Patient, General Medicine Faculty of RostGMU (Rostov State Medical University), IDH, Isocitrate dehydrogenase, MDS, University, CMML, Pharmaceutical industry, Debiopharm

LAUSANNE, Switzerland , Oct. 3, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational Research – Prof. Mamiko Sakata-Yanagimoto. The winners were honored with trophies and a monetary prize during the live event of the 81st Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Thierry Mauvernay, President of Debiopharm, and Bertrand Ducrey CEO of Debiopharm. 

Key Points: 
  • "The previous winners of the Mauvernay Award have immediately becomevery well-known scientists in our country, becoming professors and leaders in significant institutes.
  • Therefore, I would say that the Mauvernay Award is definitely a huge step for young cancer research scientists in our country."
  • Dr. Akihide Yoshimi's disruptive research at the National Cancer Center Research Institute, is aimed at understanding and targeting aberrant RNA splicing inhematological malignancies.
  • Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.

UFCW Canada lifetime fundraising for Leukemia & Lymphoma Society of Canada tops $49 million thanks to $1.86 million campaign in 2021-2022

Retrieved on: 
Friday, June 17, 2022
Â, Agriculture, COVID-19, Clonal hematopoiesis, Society, Leukemia & Lymphoma Society of Canada, The Beer Store, Lymphoma, Research, Local union, Leukemia, Lymphatic system, UFCW, United Food and Commercial Workers, National, TET2, Patient, TPO, Leukemia Research, GLOBE, Industrial and Commercial Workers' Union (Ghana), Light the Night Walk, Pension fund, Pharmaceutical industry

TORONTO, June 17, 2022 (GLOBE NEWSWIRE) -- Another year of pandemic restrictions presented unique challenges for UFCW Canadas fundraising efforts on behalf of the Leukemia & Lymphoma Society of Canada (LLSC).

Key Points: 
  • TORONTO, June 17, 2022 (GLOBE NEWSWIRE) -- Another year of pandemic restrictions presented unique challenges for UFCW Canadas fundraising efforts on behalf of the Leukemia & Lymphoma Society of Canada (LLSC).
  • Since adopting the LLSC as our charity of choice 37 years ago, UFCW has raised over $49 million in support of the Societys impactful work.
  • UFCW Canada is the country's most innovative organization dedicated to building fairness in workplaces and communities.
  • Since 1985, UFCW Canada members and Local Unions have also fundraised over $49 million in support of the life-changing work of The Leukemia & Lymphoma Society of Canada.

Bionano Genomics Announces Publication of Study Evaluating Optical Genome Mapping for High Throughput Characterization of Cytogenomic Heterogeneity in MDS

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, American Society of Hematology, FISH, Medicine, Company, Monroe Dunaway Anderson, Karyotype, Research, GLOBE, Forward-looking statement, TP53, Security (finance), CMA, Private Securities Litigation Reform Act, TET2, SV, DRS, Bone marrow, Patient, Software, Biomarker, Hospital Insurance and Diagnostic Services Act, Autism, MD Anderson Cancer Center, Method, OGM, Lineagen, MECOM, COVID-19, MDS, Adoption, University, SVS, KMT2A, Diagnosis, Doctor of Philosophy, Solution, CK, Genomics, Biology, Genome, Annual report, SAN, Society, Myelodysplastic syndrome, ASH, Algorithm, Medical imaging, Medical device

The study evaluated the utility of OGM as an alternative to traditional cytogenomic methods for the characterization of structural variation (SV) in myelodysplastic syndrome (MDS).

Key Points: 
  • The study evaluated the utility of OGM as an alternative to traditional cytogenomic methods for the characterization of structural variation (SV) in myelodysplastic syndrome (MDS).
  • MDS refers to disorders of the bone marrow in which it does not produce enough healthy blood cells.
  • Dr. Rashmi Kanagal-Shamanna from MD Anderson commented: The results of this study underscore the potential of optical genome mapping to become a single-platform cytogenetic tool for structural variant profiling in indications such as MDS.
  • Structural variant profiling is as important as sequence variant or mutation profiling for proper characterization of MDS in research and patient management.

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CBL, Twitter, Lymphatic system, Chemokine, Clinical trial, COVID-19, Inflammation, Health, Rheumatoid arthritis, Padrón, Blood, Incidence, Granulocyte-macrophage colony-stimulating factor, Warner Sallman, Judgement, National Health, RAS, Leukemia, Chronic myelomonocytic leukemia, Survival, Risk, GM-CSF, SAHMRI, Goal, III, Hypersensitivity, SEC, Medical Research Council, Government, Precision medicine, Medical Research Future Fund, Medicare, CEO, Nasdaq, Acute leukemia, Patient, Mutation, South Australian Health and Medical Research Institute, University, LinkedIn, Geography, Cancer, Hematology, Knowledge, NRAS, TET2, National Health and Medical Research Council, Azacitidine, Forward-looking statement, GM, Associate, KRAS, Progression-free survival, Pharmaceutical industry, Vaccine, Risk management, PREACH-M, Humanigen, Inc., SAHMRI, PREACH-M, HUMANIGEN, INC., SAHMRI

The PREACH-M trial is designed to focus on Chronic Myelomonocytic Leukemia (CMML) patients who carry mutations believed to drive the leukemia.

Key Points: 
  • The PREACH-M trial is designed to focus on Chronic Myelomonocytic Leukemia (CMML) patients who carry mutations believed to drive the leukemia.
  • Patients with RAS pathway mutations such as KRAS, NRAS, or CBL, will be enrolled in the lenzilumab and azacitidine arm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • A phase 1 study of lenzilumab, a humaneered recombinant anti-human granulocyte-macrophage colony- stimulating factor (anti-hGM-CSF) antibody, for chronic myelomonocytic leukemia (CMML).